Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Knowledge Gaps and Future Research Needs (2)
All future trials should be placebo controlled and double blinded. They should include prospective data collection for hospitalization, bone consequences, mortality, and HRQoL. Consensus is needed on which exercise-tolerance test and which HRQoL questionnaire to use. Prospective cohort studies should assess important long-term health outcomes in patients who have received rhGH treatment to date.
Keywords: cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.